targeted fusion protein therapy

PROCEDURE4 trials

Sponsors

INSYS Therapeutics Inc

Conditions

Anaplastic AstrocytomaAnaplastic OligodendrogliomaGlioblastoma MultiformeMalignant AstrocytomaMalignant GliomaMixed Oligoastrocytoma

Phase 1

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

CompletedNCT00024557

INSYS Therapeutics IncAnaplastic Astrocytoma, Glioblastoma Multiforme, Malignant Astrocytoma +2

Start: 2001-06-30End: 2007-07-31Target: 40Updated: 2011-06-06

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

CompletedNCT00024570

INSYS Therapeutics IncAnaplastic Astrocytoma, Glioblastoma Multiforme, Malignant Glioma +1

Start: 2000-11-30End: 2007-07-31Target: 60Updated: 2014-11-14

Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

CompletedNCT00041587

INSYS Therapeutics IncAnaplastic Astrocytoma, Glioblastoma Multiforme, Malignant Glioma +1

Start: 2002-07-31End: 2007-07-31Target: 80Updated: 2011-06-06

Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

CompletedNCT00064779

INSYS Therapeutics IncAnaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma Multiforme +2

Start: 2003-07-31End: 2007-07-31Target: 18Updated: 2011-06-06